新型青霉烯抗生素CP-70429的体外抗菌活性及β-内酰胺酶稳定性
In vitro antibacterial activity and beta-lactamase stability of CP-70,429 a new penem antibiotic.
作者信息
Minamimura M, Taniyama Y, Inoue E, Mitsuhashi S
机构信息
Episome Institute, Gunma, Japan.
出版信息
Antimicrob Agents Chemother. 1993 Jul;37(7):1547-51. doi: 10.1128/AAC.37.7.1547.
Abstract
In in vitro susceptibility tests, the new penem CP-70,429 showed potent antibacterial activity against gram-positive and gram-negative bacteria except Pseudomonas aeruginosa and Xanthomonas maltophilia. CP-70,429 was stable to various types of beta-lactamases except for the enzyme from X. maltophilia and was 16- to 128-fold more active than the other compounds against beta-lactamase-producing strains of Enterobacter cloacae and Citrobacter freundii.
摘要
在体外药敏试验中，新型青霉烯类药物CP - 70,429对革兰氏阳性菌和革兰氏阴性菌显示出强大的抗菌活性，但对铜绿假单胞菌和嗜麦芽窄食单胞菌除外。CP - 70,429对除嗜麦芽窄食单胞菌产生的酶以外的各种β - 内酰胺酶稳定，并且对阴沟肠杆菌和弗氏柠檬酸杆菌的产β - 内酰胺酶菌株的活性比其他化合物高16至128倍。
相似文献
1
In vitro antibacterial activity and beta-lactamase stability of CP-70,429 a new penem antibiotic.新型青霉烯抗生素CP-70429的体外抗菌活性及β-内酰胺酶稳定性
Antimicrob Agents Chemother. 1993 Jul;37(7):1547-51. doi: 10.1128/AAC.37.7.1547.
2
In vitro antibacterial activity and beta-lactamase stability of SY5555, a new oral penem antibiotic.新型口服青霉烯类抗生素SY5555的体外抗菌活性及β-内酰胺酶稳定性
Antimicrob Agents Chemother. 1994 Sep;38(9):1974-9. doi: 10.1128/AAC.38.9.1974.
3
Sch 34343: in-vitro antibacterial activity and susceptibility to beta-lactamases.Sch 34343：体外抗菌活性及对β-内酰胺酶的敏感性
J Antimicrob Chemother. 1985 Jun;15 Suppl C:15-23. doi: 10.1093/jac/15.suppl_c.15.
4
[Antibacterial activity of sulopenem, a new parenteral penem antibiotic].[新型肠外给药青霉烯类抗生素舒洛培南的抗菌活性]
Jpn J Antibiot. 1996 Apr;49(4):338-51.
5
MEN 10700, a new penem antibiotic: in-vitro activity and its correlation with beta-lactamase stability, PBP affinity and diffusion through the bacterial cell wall.美罗培南10700，一种新型青霉烯类抗生素：体外活性及其与β-内酰胺酶稳定性、青霉素结合蛋白亲和力和通过细菌细胞壁扩散的相关性。
J Antimicrob Chemother. 1998 May;41(5):513-25. doi: 10.1093/jac/41.5.513.
6
In vitro antibacterial activity and beta-lactamase stability of the new carbapenem SM-7338.
Eur J Clin Microbiol Infect Dis. 1989 Oct;8(10):908-16. doi: 10.1007/BF01963782.
7
Gram-negative bacilli resistant to third-generation cephalosporins: beta-lactamase characterization and susceptibility to Sch 34343.对第三代头孢菌素耐药的革兰氏阴性杆菌：β-内酰胺酶特性及对Sch 34343的敏感性
J Antimicrob Chemother. 1985 Jun;15 Suppl C:119-32. doi: 10.1093/jac/15.suppl_c.119.
8
In vitro activity and beta-lactamase stability of a new penem, CGP 31608.新型青霉烯类药物CGP 31608的体外活性及β-内酰胺酶稳定性
Antimicrob Agents Chemother. 1987 Apr;31(4):558-69. doi: 10.1128/AAC.31.4.558.
9
In-vitro activity of a new penem FCE 22101.新型青霉烯类抗生素FCE 22101的体外活性
J Antimicrob Chemother. 1989 Mar;23 Suppl C:53-7. doi: 10.1093/jac/23.suppl_c.53.
10
Antibacterial activity of T-5575, a novel 2-carboxypenam, and its stability to beta-lactamase.新型2-羧基青霉烷T-5575的抗菌活性及其对β-内酰胺酶的稳定性。
J Antimicrob Chemother. 1997 Jan;39(1):31-4. doi: 10.1093/jac/39.1.31.
引用本文的文献
1
Antibiotics in the clinical pipeline as of December 2022.截至 2022 年 12 月处于临床研发管线中的抗生素。
J Antibiot (Tokyo). 2023 Aug;76(8):431-473. doi: 10.1038/s41429-023-00629-8. Epub 2023 Jun 8.
2
Sulopenem: An Intravenous and Oral Penem for the Treatment of Urinary Tract Infections Due to Multidrug-Resistant Bacteria.舒巴坦钠：一种用于治疗多重耐药菌引起的尿路感染的静脉注射和口服青霉素类药物。
Drugs. 2022 Apr;82(5):533-557. doi: 10.1007/s40265-022-01688-1. Epub 2022 Mar 16.
3
Oral Antibiotics in Clinical Development for Community-Acquired Urinary Tract Infections.用于社区获得性尿路感染临床开发的口服抗生素
Infect Dis Ther. 2021 Dec;10(4):1815-1835. doi: 10.1007/s40121-021-00509-4. Epub 2021 Aug 6.
4
Antibiotics in the clinical pipeline in October 2019.2019 年 10 月处于临床研发管线中的抗生素。
J Antibiot (Tokyo). 2020 Jun;73(6):329-364. doi: 10.1038/s41429-020-0291-8. Epub 2020 Mar 10.
5
Activity of Sulopenem, an Oral Penem, against Urinary Isolates of .硫培南对..尿分离株的活性。
Antimicrob Agents Chemother. 2018 Dec 21;63(1). doi: 10.1128/AAC.01832-18. Print 2019 Jan.
6
In vitro antibacterial activity and beta-lactamase stability of SY5555, a new oral penem antibiotic.新型口服青霉烯类抗生素SY5555的体外抗菌活性及β-内酰胺酶稳定性
Antimicrob Agents Chemother. 1994 Sep;38(9):1974-9. doi: 10.1128/AAC.38.9.1974.
7
Comparative antimicrobial activities of the penem WY-49605 (SUN5555) against recent clinical isolates from five U.S. medical centers.青霉烯类药物WY-49605（SUN5555）对来自美国五个医疗中心的近期临床分离株的抗菌活性比较
Antimicrob Agents Chemother. 1995 Jul;39(7):1591-5. doi: 10.1128/AAC.39.7.1591.
本文引用的文献
1
A spectrophotometric assay of beta-lactamase action on penicillins.一种关于β-内酰胺酶对青霉素作用的分光光度测定法。
Biochem J. 1974 Jun;139(3):789-90. doi: 10.1042/bj1390789.
2
In vitro antibacterial activity of Sch 34343 and its stability to beta-lactamases and renal dehydropeptidase 1.Sch 34343的体外抗菌活性及其对β-内酰胺酶和肾脱氢肽酶1的稳定性
Antimicrob Agents Chemother. 1985 Nov;28(5):684-8. doi: 10.1128/AAC.28.5.684.
3
In vitro activity of CP-65,207, a new penem antimicrobial agent, in comparison with those of other agents.新型青霉烯类抗菌剂CP-65,207与其他抗菌剂相比的体外活性。
Antimicrob Agents Chemother. 1989 Aug;33(8):1160-6. doi: 10.1128/AAC.33.8.1160.
4
Characterization of beta-lactamases.β-内酰胺酶的特性分析
Antimicrob Agents Chemother. 1989 Mar;33(3):259-63. doi: 10.1128/AAC.33.3.259.
5
In vitro activity of AT-4140 against clinical bacterial isolates.AT-4140对临床分离细菌的体外活性。
Antimicrob Agents Chemother. 1989 Nov;33(11):1980-8. doi: 10.1128/AAC.33.11.1980.
6
Pharmacokinetic studies in animals of a new parenteral penem CP-65,207 and its oral prodrug ester.
J Antibiot (Tokyo). 1990 Apr;43(4):422-32. doi: 10.7164/antibiotics.43.422.
Zotero 插件